GLP-1 Medications and Kidney Disease: What the FLOW Trial Showed
A major trial found semaglutide protected the kidneys in a specific group of patients. Here is what it showed, who it applies to, and the honest limits.
The short answer
In the FLOW trial (Perkovic et al., New England Journal of Medicine, 2024; DOI 10.1056/NEJMoa2403347), semaglutide reduced the risk of major kidney events by about 24 percent in adults who had both type 2 diabetes and chronic kidney disease, compared with placebo. That is an important finding, but it applies to that specific population and is not a promise of kidney benefit for everyone.
What FLOW actually studied
FLOW enrolled adults with type 2 diabetes and chronic kidney disease and followed hard outcomes: a sustained large drop in kidney function, kidney failure, or death from kidney or cardiovascular causes. The trial was stopped early because the benefit was clear. It studied the brand injectable medication, not a compounded preparation, and the people in it had established kidney disease.
Ready to start?
$199 Skeptics’ Trial, see if it works for you
One month of medical-grade compounded semaglutide, the $119 doctor review, and a free B-12/lipotropic injection. No long-term commitment.
Start the 30-day trialHow might a GLP-1 help the kidneys?
Researchers think the benefit comes from several directions at once: weight loss, better blood-sugar control, lower blood pressure, and direct anti-inflammatory effects on the kidney. The exact mechanism is still being studied. The practical point is that the effect was measured on real outcomes, not just lab numbers.
The honest limits
This does not mean a GLP-1 is a kidney drug for the general public. FLOW studied a specific high-risk group, it used the brand medication, and kidney care is highly individual. Compounded semaglutide is not FDA-approved or brand-identical, and no clinic should imply it will protect your kidneys. If you have kidney disease, this is a conversation for your physician, who will weigh your full picture.
What we offer at New Hope Weight Loss today
After a one-time $119 medical review with Dr. Sharma, eligible patients begin a physician-supervised program with compounded semaglutide from $166 a month or compounded tirzepatide from $233 a month, with a $199 one-month Skeptics' Trial. Compounded semaglutide and tirzepatide are prepared by licensed U.S. pharmacies and are not FDA-approved, not brand-identical, and not reviewed by the FDA for safety, effectiveness, or quality. Care is delivered in person in Orange County and by telehealth across California and additional states.
Frequently asked questions
Does semaglutide protect the kidneys?
In the FLOW trial (DOI 10.1056/NEJMoa2403347), semaglutide reduced major kidney events by about 24 percent in adults who had both type 2 diabetes and chronic kidney disease. That is a meaningful result for that specific high-risk group, but it is not a guarantee of kidney benefit for everyone, and the trial used the brand medication, not a compounded one.
Was FLOW done with compounded semaglutide?
No. FLOW studied the brand injectable medication in people with type 2 diabetes and chronic kidney disease. Compounded semaglutide is prepared by a licensed U.S. pharmacy and is not FDA-approved or brand-identical, so trial results cannot be assumed to transfer to it. We are upfront about that distinction.
I have kidney disease. Can I take a GLP-1?
That depends on your full medical picture and is a decision for your physician. GLP-1 medications require dose care and monitoring, and some situations call for caution. Bring your kidney history to a medical review so a physician can decide what is safe and appropriate for you. This page is educational and not medical advice.
How much weight does semaglutide cause people to lose?
In the STEP 1 trial (PMID 33567185), adults on semaglutide 2.4 mg lost an average of about 14.9 percent of body weight at 68 weeks versus 2.4 percent on placebo. That trial used the brand medication; individual results vary and are not guaranteed.
What does New Hope Weight Loss offer for kidney patients?
We offer physician-supervised compounded semaglutide or tirzepatide after a $119 review, but every plan starts with Dr. Sharma reviewing your history, including any kidney disease, to decide what is appropriate. We do not make kidney-protection claims about compounded medication.
This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.